A phase 1, single-site, double-blind,randomized, dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of intravenous bolus or intravenous bolus followed by continuous infusion administration of ARC1779 [Archemix Corporation] compared to placebo in healthy volunteers

Trial Profile

A phase 1, single-site, double-blind,randomized, dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of intravenous bolus or intravenous bolus followed by continuous infusion administration of ARC1779 [Archemix Corporation] compared to placebo in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2007

At a glance

  • Drugs Egaptivon pegol (Primary)
  • Indications Thrombosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 04 Dec 2007 Results have been published in Circulation
    • 19 Apr 2007 Status changed from 'recruiting' to 'completed'
    • 08 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top